Breaking News: Atossa Therapeutics Receives Extended Patent Protection for Endoxifen – A Major Milestone for Breast Cancer Treatment

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS)

Exciting news has emerged in the field of breast cancer treatment as Atossa Therapeutics, a renowned biopharmaceutical company, has received extended patent protection for Endoxifen, a promising compound that could revolutionize the way we approach breast cancer therapy. The United States Patent and Trademark Office (USPTO) has granted Atossa a new patent (U.S. Patent No. 12,071,391) specifically focused on compositions comprising Endoxifen in free base or salt forms, combined with an enteric material where at least 90 percent of the Endoxifen is in the (Z)-Endoxifen form. This patent also includes methods for administering these compositions to patients, marking a significant milestone in the fight against breast cancer.

Atossa Therapeutics has been committed to developing innovative medicines to address unmet medical needs in the field of oncology, with a particular focus on breast cancer. Endoxifen, a metabolite of the FDA-approved breast cancer medication tamoxifen, has shown great potential in improving outcomes for breast cancer patients. By securing extended patent protection for this compound, Atossa Therapeutics is set to pave the way for novel and effective treatment options that could potentially save countless lives.

This groundbreaking development not only showcases the dedication and expertise of the team at Atossa Therapeutics but also underscores the importance of continued research and innovation in the field of oncology. With breast cancer being one of the most prevalent forms of cancer affecting women worldwide, the need for advanced and targeted therapies has never been more pressing. The extended patent protection for Endoxifen represents a significant step towards fulfilling this need and brings hope to patients and healthcare providers alike.

As we look towards the future, the implications of this milestone for breast cancer treatment are profound. The availability of extended patent protection for Endoxifen could lead to accelerated clinical trials, expedited regulatory approvals, and ultimately, improved outcomes for patients battling breast cancer. By investing in research and development efforts focused on innovative therapies like Endoxifen, Atossa Therapeutics is demonstrating a commitment to advancing the field of oncology and making a meaningful impact on the lives of those affected by this devastating disease.

How This Will Affect Me

For individuals diagnosed with breast cancer, the extended patent protection for Endoxifen offers a glimmer of hope in the form of potentially more effective treatment options. This development could lead to the availability of novel therapies that target breast cancer with greater precision, ultimately improving outcomes and quality of life for patients. The groundbreaking research and innovation behind Endoxifen underscore the ongoing efforts to advance cancer treatment and provide individuals with new avenues for fighting this disease.

How This Will Affect the World

The impact of Atossa Therapeutics receiving extended patent protection for Endoxifen extends far beyond individual patients, with the potential to revolutionize breast cancer treatment on a global scale. By investing in innovative therapies and securing patent protection for key compounds like Endoxifen, companies like Atossa are driving progress in the field of oncology and paving the way for more effective and targeted cancer therapies. This milestone represents a significant advancement in the fight against breast cancer and offers hope for improved outcomes for patients worldwide.

Conclusion

The news of Atossa Therapeutics receiving extended patent protection for Endoxifen is a major milestone in the field of breast cancer treatment, signaling a new era of innovation and hope for patients battling this devastating disease. This development has the potential to not only impact individual patients by offering promising treatment options but also to revolutionize breast cancer therapy on a global scale. Through continued research, investment, and collaboration, we can look forward to a future where advanced therapies like Endoxifen play a crucial role in improving outcomes and saving lives in the fight against breast cancer.